and care of children and adolescents with AML in Europe can be formulated: (i) the cumulative nonleukemic death rate (including early deaths due to hemorrhage or acute respiratory distress syndrome, deaths in complete remission, e.g., due to infections, and treatment-related mortality of SCT) should be less than 10 % of all patients; (ii) there should be less than 35 % of patients suffering from a relapse and more than 65 % overall should be cured (the latter may include about 10 % of all patients who can be cured after a first relapse); (iii) about 90 % of patients with lower-risk genetics (i.e., up to 35 % of all pediatric AMLs as characterized by translocations PML-RARA, RUNX1-RUNX1T1 (AML1-ETO), CBFB-MYH11, or by GATA-1 mutation) should be long-term surviving; (iv) at least one SCT is needed in another group of about 35 % of all patients-many but not all of whom can nowadays be predefined based on diagnostic algorithms-to safeguard a chance of cure, but this unfortunately remains without a guarantee of long-term success.
Academic treatment trials and the dedicated input of involved stakeholders have led to these respectable improvements in the outcome of a disease, which was considered mostly incurable just 40 years ago. But driving cure rates further up until most-if not all-children with AML are to be saved will need extraordinary input not only of academia and clinical teams, but also of society, regulators, and pharmaceutical industry. Undoubtedly, there are important societal implications when it comes to financing both, standard care with appropriate diagnostics and the validated treatment backbone (which is available as outlined by the plenitude of data now published also herein), as well as research including data registration, observation, and analysis for the benefit of patients [11] . Some obstacles to this end need to be turned down by the regulators themselves because they are just created by current regulations or their interpretation. For example, it will be most important for the understanding of the quality of care to reg-ister all those patients who present first as emergency case or even die very early irrespectively of whether or not they enter a clinical trial. Clearly, this is problematic with respect to the need of obtaining informed consent for trial participation in an emergency situation. Hence, not being able to obtain written consent before event occurrence may lead to important selection bias. Hence, trial policies permitting waivers of prior informed consent for minimal-risk observational research are urgently needed as are policies that allow a better linkage of registries with randomized treatment trials on top [12] . This may allow observing all diseased patients and their treatment course based on a standard backbone therapy upon inclusion into low-cost observational registries toward composite end-points. In addition, this may allow us to concomitantly conduct randomized assessments of specific questions (with a higher degree of risk) among subcohorts of patients of the registry for a limited period of observation [13] . A better understanding of the issues at the regulator level may lead to more appropriate design and interpretation of regulations for academia-driven clinical trials. Eventually, this should lead to the expectation of the society that participation in clinical registries complemented with randomized treatment optimization trials is the norm rather than the exception when it comes to care for children and adolescents with cancer [14] .
This latter aspect is particularly momentous when realizing that four out of the six most important chemotherapeutic drugs used in the AML-BFM backbone treatment (which allow for the respectable cure rates of children with AML delineated herein) are still not licensed for the treatment of children and adolescents in Europe (i.e., mitoxantrone, idarubicin, liposomal daunorubicin, and 2-CdA). Over those 35 years of clinical trials, however, dedicated work of academia has elaborated a surplus of information on outcome end-points and cumulative toxicities when using these drugs in combinations throughout all age groups of childhood, with no chance to generate an impact on market authorization and labeling. It was clearly shown that those off-label drugs save more lives than could be saved by using just drugs with market authorization [15] [16] [17] [18] [19] . Hence, the question of label should be separated from market authorization and economic interests by creating an evidence-based clinical application label. One can definitely accept that the current AML-BFM backbone has produced sufficient evidence to consider those six most important drugs included as "labeled" for curing children and adolescents with AML. And in that context, despite being off-label with respect to marketing, these established chemotherapeutic drugs and their combinations in the AML-BFM backbone do not need to be considered investigational medicinal products sensu strictu when new trials for treatment optimization are to be submitted to dedicated authorities and ethics boards.
In conclusion, we have come far in caring for and curing children and adolescents with AML-but we need significant joint efforts of all stakeholders including also society, regulators, and even the pharmaceutical industry and the willingness for a change-to come even farer toward our goal which is curing all children and adolescents with AML.
